共 8 条
[1]
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial[J] Esler Murray D;Krum Henry;Sobotka Paul A;Schlaich Markus P;Schmieder Roland E;Böhm Michael The Lancet 2010,
[2]
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J] Henry Krum;Markus Schlaich;Rob Whitbourn;Paul A Sobotka;Jerzy Sadowski;Krzysztof Bartus;Boguslaw Kapelak;Anthony Walton;Horst Sievert;Suku Thambar;William T Abraham;Murray Esler The Lancet 2009,
[3]
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II; double-blind; randomised trial[J] Yusuf S;Pais P;Afzal R;Xavier D;Teo K;Eikelboom J;Sigamani A;Mohan V;Gupta R;Thomas N The Lancet 2009,
[4]
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document[J] Giuseppe Mancia;Stéphane Laurent;Enrico Agabiti-Rosei;Ettore Ambrosioni;Michel Burnier;Mark J. Caulfield;Renata Cifkova;Denis Clément;Antonio Coca;Anna Dominiczak;Serap Erdine;Robert Fagard;Csaba Farsang;Guido Grassi;Hermann Haller;Antony Heagerty;Sverre E. Kjeldsen;Wolfgang Kiowski;Jean Michel Mallion;Athanasios Manolis;Krzysztof Narkiewicz;Peter Nilsson;Michael
[5]
Oral Direct Renin Inhibition: Premise; Promise; and Potential Limitations of a New Antihypertensive Drug[J] Moiz M. Shafiq;Dileep V. Menon;Ronald G. Victor The American Journal of Medicine 2008,
[6]
Relation of Beta-Blocker–Induced Heart Rate Lowering and Cardioprotection in Hypertension[J] Sripal Bangalore;Sabrina Sawhney;Franz H. Messerli Journal of the American College of Cardiology 2008,
[7]
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients[J] Kenneth Jamerson;Michael A. Weber;George L. Bakris;Björn Dahlöf;Bertram Pitt;Victor Shi;Allen Hester;Jitendra Gupte;Marjorie Gatlin;Eric J. Velazquez The New England Journal of Medicine 2008,
[8]
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis[J] Lars Hjalmar Lindholm;Bo Carlberg;Ola Samuelsson The Lancet 2005,